Lorenzo-Lupo Dei

Dr. Lorenzo-Lupo Dei

Università degli studi dell'Aquila, L’Aquila, Abruzzo, Italy
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
MZMattia Zampieri
Mattia Zampieri
GEGiacomo Emmi
Giacomo Emmi
MBMatteo Beltrami
Matteo Beltrami
CFCarlo Fumagalli
Carlo Fumagalli
MUMaria Letizia Urban
Maria Letizia Urban
DPDomenico Prisco
Domenico Prisco

17 June 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
LDLorenzo-Lupo Dei
Lorenzo-Lupo Dei
Jennie HanJennie Han
Jennie Han
SRSilvio ROMANO
Silvio ROMANO
Sciarra LuigiSciarra Luigi
Sciarra Luigi
AAAngeliki Asimaki
Angeliki Asimaki
GFGherardo Finocchiaro
Gherardo Finocchiaro
Arrhythmogenic cardiomyopathy (ACM) is an inherited cardiac condition, often caused by mutations in genes encoding desmosomal proteins. The pathologic hallmark of the disease is a fibrofatty replacement of the myocardium, which constitutes the substrate for potentially fatal ventricular arrhythmias. ACM is one of the most common etiology of sudden cardiac death in athletes and young individuals. Although it is well established that regular exercise confers multiple health benefits and better survival in the general population, intense exercise may accelerate the phenotypic expression and the propensity to ventricular arrhythmias in patients with ACM. This review discusses current evidence regarding the safety and the effects of exercise in ACM. We scrutinize research findings based on animal and human models that raise concerns on the possible detrimental role of intense exercise in this condition. Finally, we examine the current knowledge on exercise prescription focusing on the optimal amount of exercise that should be recommended to patients with ACM.

17 April 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MBMatteo Beltrami
Matteo Beltrami
MMMassimo Milli
Massimo Milli
LDLorenzo-Lupo Dei
Lorenzo-Lupo Dei
APAlberto Palazzuoli
Alberto Palazzuoli
Patients with heart failure (HF) and associated chronic kidney disease (CKD) are a population less represented in clinical trials; additionally, subjects with more severe estimated glomerular filtration rate reduction are often excluded from large studies. In this setting, most of the data come from post hoc analyses and retrospective studies. Accordingly, in patients with advanced CKD, there are no specific studies evaluating the long-term effects of the traditional drugs commonly administered in HF. Current concerns may affect the practical approach to the traditional treatment, and in this setting, physicians are often reluctant to administer and titrate some agents acting on the renin angiotensin aldosterone system and the sympathetic activity. Therefore, the extensive application in different HF subtypes with wide associated conditions and different renal dysfunction etiologies remains a subject of debate. The role of novel drugs, such as angiotensin receptor blocker neprilysin inhibitors and sodium glucose linked transporters 2 inhibitors seems to offer a new perspective in patients with CKD. Due to its protective vascular and hormonal actions, the use of these agents may be safely extended to patients with renal dysfunction in the long term. In this review, we discussed the largest trials reporting data on subjects with HF and associated CKD, while suggesting a practical stepwise algorithm to avoid renal and cardiac complications.

Verified
Journal Article
Open access
PDF file
ASAntonio Scarà
Antonio Scarà
ZPZefferino Palamà
Zefferino Palamà
ARAntonio Gianluca Robles
Antonio Gianluca Robles
LDLorenzo-Lupo Dei
Lorenzo-Lupo Dei
ABAlessio Borrelli
Alessio Borrelli
Sciarra LuigiSciarra Luigi
Sciarra Luigi
Heart failure (HF) represents a significant global health challenge that is still responsible for increasing morbidity and mortality despite advancements in pharmacological treatments. This review investigates the effectiveness of non-pharmacological interventions in the management of HF, examining lifestyle measures, physical activity, and the role of some electrical therapies such as catheter ablation, cardiac resynchronization therapy (CRT), and cardiac contractility modulation (CCM). Structured exercise training is a cornerstone in this field, demonstrating terrific improvements in functional status, quality of life, and mortality risk reduction, particularly in patients with HF with reduced ejection fraction (HFrEF). Catheter ablation for atrial fibrillation, premature ventricular beats, and ventricular tachycardia aids in improving left ventricular function by reducing arrhythmic burden. CRT remains a key intervention for selected HF patients, helping achieve left ventricular reverse remodeling and improving symptoms. Additionally, the emerging therapy of CCM provides a novel opportunity for patients who do not meet CRT criteria or are non-responders. Integrating non-pharmacological interventions such as digital health alongside specific medications is key for optimizing outcomes in HF management. It is imperative to tailor approaches to individual patients in this diverse patient population to maximize benefits. Further research is warranted to improve treatment strategies and enhance patient outcomes in HF management.

4 August 2022 in Life
Verified
Journal Article
Open access
PDF file
MBMatteo Beltrami
Matteo Beltrami
LDLorenzo-Lupo Dei
Lorenzo-Lupo Dei
MMMassimo Milli
Massimo Milli
In recent years, new interest is growing in the left atrium (LA). LA functional analysis and measurement have an essential role in cardiac function evaluation. Left atrial size and function are key elements during the noninvasive analysis of diastolic function in several heart diseases. The LA represents a “neuroendocrine organ” with high sensitivity to the nervous, endocrine, and immune systems. New insights highlight the importance of left atrial structural, contractile, and/or electrophysiological changes, introducing the concept of “atrial cardiomyopathy”, which is closely linked to underlying heart disease, arrhythmias, and conditions such as aging. The diagnostic algorithm for atrial cardiomyopathy should follow a stepwise approach, combining risk factors, clinical characteristics, and imaging. Constant advances in imaging techniques offer superb opportunities for a comprehensive evaluation of LA function, underlying specific mechanisms, and patterns of progression. In this literature review, we aim to suggest a practical, stepwise algorithm with integrative multimodality imaging and a clinical approach for LA geometry and functional analysis. This integrates diastolic flow analysis with LA remodelling by the application of traditional and new diagnostic imaging techniques in several clinical settings such as heart failure (HF), atrial fibrillation (AF), coronary artery disease (CAD), and mitral regurgitation (MR).

24 October 2025 in Polish Heart Journal
Verified
Journal Article
Open access
PDF file
LDLorenzo-Lupo Dei
Lorenzo-Lupo Dei
GHGeza Halasz
Geza Halasz
PCPaolo Ciacci
Paolo Ciacci
GGGuido Giacalone
Guido Giacalone
MBMatteo Beltrami
Matteo Beltrami
DGDomenico Gabrielli
Domenico Gabrielli